PPAR gamma agonists for treating illnesses with pathophysiological participation of TH17 lymphocytes

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent covers the use of one or more PPAR gamma (PPARγ) agonists as a treatment for diseases where T helper 17 cells (TH17 lymphocytes) play a key pathological role. By activating PPARγ in specific immune cells, particularly CD4+ T-cells, it reduces their differentiation into TH17 cells and suppresses the production of inflammatory molecules. This mechanism is proposed to provide a targeted therapy for a range of autoimmune and inflammatory diseases associated with TH17 cells, such as multiple sclerosis, rheumatoid arthritis, Crohn's disease, psoriasis, and others.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of multiple sclerosis to reduce disease activity via suppression of TH17-mediated inflammation.
• Therapy for rheumatoid arthritis by limiting the inflammatory actions of TH17 cells.
• Management of chronic inflammatory bowel diseases such as Crohn's disease and ulcerative colitis.
• Treatment of psoriasis by reducing autoimmune skin inflammation.
• Therapy for systemic lupus erythematosus (SLE).
• Reduction of inflammation in acute coronary syndromes linked to TH17 activity.
• Adjunctive therapy for patients with allergic asthma where TH17 cells contribute to disease.
• Novel treatment for cerebrovascular events where TH17 cells are implicated.
• Improved therapies for patients resistant to existing immunosuppressive or immunomodulatory drugs.

BenefitsContent extracted from patent full text and abstract with AI.

• Selective targeting of TH17 cells may result in better disease control with fewer side effects compared to broad-spectrum immunosuppression.
• Potential to treat a wide variety of autoimmune and inflammatory diseases sharing a common pathophysiological mechanism.
• Existing PPARγ agonists (some already approved for other indications) can potentially be repurposed for autoimmune disease treatment, possibly speeding clinical adoption.
• Oral or injectable administration options provide flexibility in patient care.
• Demonstrated efficacy in preclinical (animal and in vitro human) models, supporting translational potential.
• Mechanism allows reduction of pathogenic immune responses without broadly suppressing all immune function, possibly reducing infection risk.
• Can serve as monotherapy or in combination with other immunomodulatory agents for patients resistant to standard treatments.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

Use of one or more peroxisome proliferator-activated receptor (PPAR)-gamma agonists for treating a disease in which T helper 17 (TH17) cells have a pathophysiologically relevant function, is claimed. ACTIVITY : Antiarthritic; Antirheumatic; Antipsoriatic; Neuroprotective; Antiinflammatory; Gastrointestinal-Gen.; Antiulcer; Dermatological; Immunosuppressive; Cerebroprotective; Antiasthmatic; Cardiant; Vasotropic. MECHANISM OF ACTION : PPAR-gamma agonist; ROR-gamma t factor inhibitor.